GIUSTOZZI, MICHELA
 Distribuzione geografica
Continente #
NA - Nord America 1.394
AS - Asia 1.094
EU - Europa 869
SA - Sud America 218
AF - Africa 23
OC - Oceania 2
Continente sconosciuto - Info sul continente non disponibili 1
Totale 3.601
Nazione #
US - Stati Uniti d'America 1.359
SG - Singapore 573
IT - Italia 225
IE - Irlanda 220
CN - Cina 182
BR - Brasile 176
HK - Hong Kong 158
RU - Federazione Russa 143
VN - Vietnam 87
DE - Germania 86
FI - Finlandia 43
GB - Regno Unito 33
SE - Svezia 28
KR - Corea 22
CA - Canada 16
AT - Austria 13
MX - Messico 13
AR - Argentina 12
FR - Francia 12
IN - India 12
NL - Olanda 12
UA - Ucraina 12
PL - Polonia 10
JP - Giappone 8
ZA - Sudafrica 8
BE - Belgio 7
TR - Turchia 7
VE - Venezuela 7
CO - Colombia 6
EC - Ecuador 6
ES - Italia 6
IQ - Iraq 6
JO - Giordania 6
LT - Lituania 6
PK - Pakistan 5
BD - Bangladesh 4
CH - Svizzera 4
EG - Egitto 4
IL - Israele 4
PY - Paraguay 4
AE - Emirati Arabi Uniti 3
CL - Cile 3
CZ - Repubblica Ceca 3
GR - Grecia 3
ID - Indonesia 3
KE - Kenya 3
LB - Libano 3
PE - Perù 3
UZ - Uzbekistan 3
DZ - Algeria 2
MA - Marocco 2
OM - Oman 2
RO - Romania 2
SA - Arabia Saudita 2
TT - Trinidad e Tobago 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AI - Anguilla 1
AZ - Azerbaigian 1
DK - Danimarca 1
ET - Etiopia 1
GP - Guadalupe 1
GT - Guatemala 1
JM - Giamaica 1
LK - Sri Lanka 1
LY - Libia 1
ML - Mali 1
NZ - Nuova Zelanda 1
PF - Polinesia Francese 1
PS - Palestinian Territory 1
TJ - Tagikistan 1
TN - Tunisia 1
UY - Uruguay 1
Totale 3.601
Città #
Singapore 389
Chandler 236
Dublin 219
Hong Kong 158
San Mateo 97
Altamura 80
Perugia 71
Ashburn 66
Santa Clara 65
Boardman 60
Beijing 54
Medford 53
Lawrence 52
Princeton 52
Moscow 45
Munich 42
Los Angeles 35
Wilmington 33
Redmond 29
Andover 27
Des Moines 27
New York 26
Dong Ket 25
Ho Chi Minh City 24
Seoul 22
Turku 20
São Paulo 18
The Dalles 18
Hanoi 17
Redwood City 16
Columbus 14
Helsinki 13
Nuremberg 12
Dallas 10
Norwalk 9
Rome 9
Saint Petersburg 9
Shanghai 9
Ancona 8
Chicago 8
Piscataway 8
Tokyo 8
Amsterdam 7
Brussels 7
Denver 7
Falls Church 7
Warsaw 7
Falkenstein 6
Houston 6
Johannesburg 6
Montreal 6
Orem 6
Rio de Janeiro 6
San Paolo di Civitate 6
Stockholm 6
Amman 5
Brooklyn 5
Seattle 5
Ann Arbor 4
Bexley 4
Brasília 4
Guarulhos 4
Manchester 4
Mumbai 4
Poplar 4
Quito 4
Asunción 3
Atlanta 3
Belo Horizonte 3
Buenos Aires 3
Cairo 3
Campina Grande 3
Caracas 3
Chennai 3
Córdoba 3
Hefei 3
Juiz de Fora 3
Lima 3
London 3
Mexico City 3
Milan 3
Mineral de la Reforma 3
Nairobi 3
Olomouc 3
San Francisco 3
San Jose 3
Vienna 3
Baghdad 2
Bismarck 2
Biên Hòa 2
Bogotá 2
Bologna 2
Bolzano 2
Cabo de Santo Agostinho 2
Calgary 2
Campinas 2
Caruaru 2
Curitiba 2
Fairfield 2
Fazenda Rio Grande 2
Totale 2.412
Nome #
Causes and Risk Factors of Cerebral Ischemic Events in Patients with Atrial Fibrillation Treated with Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention: The RENo Study 97
Anticoagulation in patients with isolated distal deep vein thrombosis: a meta-analysis 93
Non-cirrhotic Extra-Hepatic Porto-Systemic Shunt Causing Adult-Onset Encephalopathy Treated with Endovascular Closure 89
Anticoagulation for atrial fibrillation in patients with active cancer: Reply to the ‘Letter to the Editor’ from Dr. Sorigue et al 84
Patients aged 90  years or older with atrial fibrillation treated with oral anticoagulants: A multicentre observational study 83
Risk of recurrent venous thromboembolism after acute pulmonary embolism: Role of residual pulmonary obstruction and persistent right ventricular dysfunction. A meta-analysis 81
Timing of initiation of oral anticoagulants in patients with acute ischemic stroke and atrial fibrillation comparing posterior and anterior circulation strokes 81
Incidence and risk factors for venous thromboembolism after laparoscopic surgery for colorectal cancer 80
Data on the use of oral anticoagulants in nonagenarians with atrial fibrillation 80
Lower dose direct oral anticoagulants and improved survival: A combined analysis in patients with established atherosclerosis 78
Safety of Anticoagulation in Patients Treated with Urgent Reperfusion for Ischemic Stroke Related to Atrial Fibrillation 76
Lo studio EINSTEIN CHOICE 76
Use of non-vitamin K antagonist oral anticoagulants for non-valvular atrial fibrillation in real-life: comparison with phase III trials 75
Oral Anticoagulants in the Oldest Old with Recent Stroke and Atrial Fibrillation 75
Incidence of venous thromboembolism in patients undergoing laparoscopic surgery for colorectal cancer 74
Variation of renal function over time is associated with major bleeding in patients treated with direct oral anticoagulants for atrial fibrillation 74
Patients with cancer and atrial fibrillation treated with doacs: A prospective cohort study 74
Padua prediction score or clinical judgment for decision making on antithrombotic prophylaxis: a quasi-randomized controlled trial 73
Beyond the guidelines: Novelties, changes and unsolved issues from the 2019 ESC guidelines on pulmonary embolism 73
Grey zones on the use of new oral anticoagulants in atrial fibrillation. Expert opinion 73
Incident Atrial Fibrillation, Dementia and the Role of Anticoagulation: A Population-Based Cohort Study 73
Permanent discontinuation of non vitamin K oral anticoagulants in real life patients with non-valvular atrial fibrillation 71
Safety of direct oral anticoagulants versus traditional anticoagulants in venous thromboembolism 71
Rates and Determinants for the Use of Anticoagulation Treatment before Stroke in Patients with Known Atrial Fibrillation 71
Long-term outcome in patients with non-valvular atrial fibrillation on dabigatran: a prospective cohort study 70
Direct Oral Anticoagulants for the Treatment of Acute Venous Thromboembolism Associated with Cancer: A Systematic Review and Meta-Analysis 68
Effects of Direct Oral Anticoagulants' Nonrecommended Dose in Atrial Fibrillation: A Meta-Analysis 67
Concomitant Use of Direct Oral Anticoagulants and Antiepileptic Drugs: A Prospective Cohort Study in Patients with Atrial Fibrillation 67
Risk Factors for Intracerebral Hemorrhage in Patients with Atrial Fibrillation on Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention 64
Risk of recurrent stroke in patients with atrial fibrillation treated with oral anticoagulants alone or in combination with anti-platelet therapy 63
Variation in the Association between Antineoplastic Therapies and Venous Thromboembolism in Patients with Active Cancer 62
Efficacy and safety of anticoagulant agents in patients with venous thromboembolism and cancer: A network meta-analysis 61
Vascular events with immune checkpoint inhibitors in melanoma or non-small cell lung cancer: A systematic review and meta-analysis 61
Treatment of venous thromboembolism in patients with cancer: What news from clinical trials? 59
Venous thromboembolism and cancer: Current and future role of direct-acting oral anticoagulants 59
The EINSTEIN CHOICE study 57
Vitamin K and non-vitamin K antagonists oral anticoagulants for non-valvular atrial fibrillation in real-life 56
Perirectal Hematoma and Intra-Abdominal Bleeding after Stapled Hemorrhoidopexy and STARR—A Proposal for a Decision-Making Algorithm 56
Management of Anticoagulant Treatment and Anticoagulation-Related Complications in Nonagenarians 56
Real-life use of non-vitamin K antagonist oral anticoagulants in comparison with vitamin K antagonists for non-valvular atrial fibrillation: data from a prospective cohort 53
Ten questions on venous thromboembolism 53
Thrombotic Complications in Patients with COVID-19: Pathophysiological Mechanisms, Diagnosis, and Treatment 53
The role of computed tomography angiography 3D imaging in post-operative haemorrhage after groin mesh hernioplasty during anticoagulation therapy 52
Total parenteral nutrition-induced Wernicke's encephalopathy after oncologic gastrointestinal surgery 51
The risk of stroke recurrence in patients with atrial fibrillation and reduced ejection fraction 50
Safety of catheter ablation of atrial fibrillation in cancer survivors 48
DOACs in patients with brain cancers: promising but still a long way to go 46
Sex-specific differences in the presentation, clinical course, and quality of life of patients with acute venous thromboembolism according to baseline risk factors. Insights from the PREFER in VTE 45
Management of heavy menstrual bleeding during direct oral anticoagulant therapy for recurrent venous thromboembolism: A case report 44
Risk factors for recurrence and major bleeding in patients with cancer-associated venous thromboembolism 43
Safety and efficacy of concomitant treatment with non-vitamin K antagonist oral anticoagulants and antiseizure medications: A propensity score matching cohort study 41
Venous thromboembolism and COVID-19: Mind the gap between clinical epidemiology and patient management 41
Risk factors and one-year mortality in patients with direct oral anticoagulant-associated gastrointestinal bleeding 41
Thrombolysis in hemodynamically stable patients with acute pulmonary embolism: A meta-analysis 39
ICH in primary or metastatic brain cancer patients with or without anticoagulant treatment: a systematic review and meta-analysis 38
Patients with Atrial Fibrillation receiving NOACs: The boundary between appropriate and inappropriate dose 37
The possible clinical impact of a threshold left atrial diameter associated with new AF in ESUS patients 35
Shock and diffuse ST-elevation in a patient with coronavirus disease-2019 disease 33
Safety and effectiveness of oral anticoagulants in patients with atrial fibrillation and stage 4 chronic kidney disease: a real-world experience 31
Reversal of dabigatran-associated bleeding using idarucizumab: review of the current evidence 29
Acute venous thromboembolism in patients with brain cancer: clinical course 25
Derivation and validation of the Caravaggio score for the risk stratification for recurrence in patients with cancer-associated venous thromboembolism 14
Totale 3.743
Categoria #
all - tutte 20.239
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 20.239


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202164 0 0 0 0 0 15 8 4 3 8 1 25
2021/2022390 1 70 5 9 19 3 6 106 12 39 64 56
2022/2023821 54 190 9 46 58 91 0 38 296 3 27 9
2023/2024334 29 38 21 6 5 0 81 5 12 26 54 57
2024/2025884 9 67 27 62 97 61 29 52 187 62 142 89
2025/2026993 152 122 95 242 265 117 0 0 0 0 0 0
Totale 3.743